These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 30853558)

  • 1. Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility.
    Xu H; Wang B; Ono M; Kagita A; Fujii K; Sasakawa N; Ueda T; Gee P; Nishikawa M; Nomura M; Kitaoka F; Takahashi T; Okita K; Yoshida Y; Kaneko S; Hotta A
    Cell Stem Cell; 2019 Apr; 24(4):566-578.e7. PubMed ID: 30853558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9 Ribonucleoprotein Complex-Mediated Efficient B2M Knockout in Human Induced Pluripotent Stem Cells (iPSCs).
    Thongsin N; Wattanapanitch M
    Methods Mol Biol; 2022; 2454():607-624. PubMed ID: 33945142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of immunocompatible pluripotent stem cells via CRISPR-based human leukocyte antigen engineering.
    Jang Y; Choi J; Park N; Kang J; Kim M; Kim Y; Ju JH
    Exp Mol Med; 2019 Jan; 51(1):1-11. PubMed ID: 30617277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of individualized immunocompatible endothelial cells from HLA-I-matched human pluripotent stem cells.
    Song C; Wang L; Li Q; Liao B; Qiao W; Li Q; Dong N; Li L
    Stem Cell Res Ther; 2022 Feb; 13(1):48. PubMed ID: 35109922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
    Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
    Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Derivation of induced pluripotent stem cells line (RCPCMi007-A-1) with inactivation of the beta-2-microglobulin gene by CRISPR/Cas9 genome editing.
    Bogomiakova ME; Sekretova EK; Eremeev AV; Shuvalova LD; Bobrovsky PA; Zerkalenkova EA; Lebedeva OS; Lagarkova MA
    Stem Cell Res; 2021 Aug; 55():102451. PubMed ID: 34237591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fit-For-All iPSC-Derived Cell Therapies and Their Evaluation in Humanized Mice With NK Cell Immunity.
    Flahou C; Morishima T; Takizawa H; Sugimoto N
    Front Immunol; 2021; 12():662360. PubMed ID: 33897711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 Genome Editing of Human-Induced Pluripotent Stem Cells Followed by Granulocytic Differentiation.
    Dannenmann B; Nasri M; Welte K; Skokowa J
    Methods Mol Biol; 2020; 2115():471-483. PubMed ID: 32006418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-Cell Mediated Immune Rejection of Beta-2-Microglobulin Knockout Induced Pluripotent Stem Cell-Derived Kidney Organoids.
    Gaykema LH; van Nieuwland RY; Lievers E; Moerkerk WBJ; de Klerk JA; Dumas SJ; Kers J; Zaldumbide A; van den Berg CW; Rabelink TJ
    Stem Cells Transl Med; 2024 Jan; 13(1):69-82. PubMed ID: 37843402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status and future perspectives of HLA-edited induced pluripotent stem cells.
    Koga K; Wang B; Kaneko S
    Inflamm Regen; 2020; 40():23. PubMed ID: 33014207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application.
    Kitano Y; Nishimura S; Kato TM; Ueda A; Takigawa K; Umekage M; Nomura M; Kawakami A; Ogawa H; Xu H; Hotta A; Takasu N; Tsukahara M
    Mol Ther Methods Clin Dev; 2022 Sep; 26():15-25. PubMed ID: 35755947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient Gene Editing of Human Induced Pluripotent Stem Cells Using CRISPR/Cas9.
    Yumlu S; Bashir S; Stumm J; Kühn R
    Methods Mol Biol; 2019; 1961():137-151. PubMed ID: 30912045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of B2M bi-allelic knockout human induced pluripotent stem cells (MUSIi001-A-1) using a CRISPR/Cas9 system.
    Thongsin N; Wattanapanitch M
    Stem Cell Res; 2021 Oct; 56():102551. PubMed ID: 34628247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoimmunogenic Human Pluripotent Stem Cells as a Powerful Tool for Liver Regenerative Medicine.
    Trionfini P; Romano E; Varinelli M; Longaretti L; Rizzo P; Giampietro R; Caroli A; Aiello S; Todeschini M; Casiraghi F; Remuzzi G; Benigni A; Tomasoni S
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9-Mediated Genome Editing to Generate Clonal iPSC Lines.
    Sanjurjo-Soriano C; Erkilic N; Mamaeva D; Kalatzis V
    Methods Mol Biol; 2022; 2454():589-606. PubMed ID: 33755901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrate CRISPR/Cas9 for protein expression of HLA-B*38:68Q via precise gene editing.
    Yin Y; Reed EF; Zhang Q
    Sci Rep; 2019 May; 9(1):8067. PubMed ID: 31147565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity.
    Tsuneyoshi N; Hosoya T; Takeno Y; Saitoh K; Murai H; Amimoto N; Tatsumi R; Watanabe S; Hasegawa Y; Kikkawa E; Goto K; Nishigaki F; Tamura K; Kimura H
    Stem Cell Res Ther; 2024 Jul; 15(1):193. PubMed ID: 38956724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-Cas9-mediated disruption of B2M and CIITA genes eliminates HLA class I and II expression in human induced pluripotent stem cells (MUSIi001-A-2).
    Thongsin N; Suwanpitak S; Wattanapanitch M
    Stem Cell Res; 2023 Sep; 71():103138. PubMed ID: 37343428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen Presentation by Individually Transferred HLA Class I Genes in HLA-A, HLA-B, HLA-C Null Human Cell Line Generated Using the Multiplex CRISPR-Cas9 System.
    Hong CH; Sohn HJ; Lee HJ; Cho HI; Kim TG
    J Immunother; 2017; 40(6):201-210. PubMed ID: 28604557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.
    Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X
    Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.